| Antibody (585) |  |
| Antigen (151) | |
| Immunity (99) | |
| Immunization (32) | |
| Immunology (64) | |
| Antibody (585) | |
| Antigen (151) | |
| Immunity (99) | |
| Immunization (32) | |
| Immunology (64) | |
and with over three times the sensitivity of current prostate specific-antigen antigen (PSA) screening. The study appears in the January issue of Clinical Chemistry (volume 61, page 239),
and display pieces of viral or bacterial proteins (known as antigens) on their cell surfaces. When these B cells encounter T cells with receptors that recognize the antigen,
the T cells become activated, provoking them to release cytokines inflammatory chemicals that control the immune response
the MIT team found that they did not all respond the same way after encountering B cells carrying identical antigens on their surfaces.
the researchers found that the initial activation level depends on how much of the antigen is presented. At high levels, most of the cells respond the same way.
at lower antigen levels, the T cell responses vary greatly. These differences also correlated to differences in T cell cytokine production.
In another twist, combining the antigen (the vaccine) and Cpg causes the body to change its immune response,
In lab tests, the Cpg-antigen package, at 300 nanometers in size, was absorbed 90 percent of the time by immune cells.
if HIV positive antibodies to HIV bind to the antigens on the plate. For this test the team was able to perform an objective read-out similar to an ELISA assay but without the spending the typical $18450 equipment cost involved.
A PSA test is currently the most common, noninvasive means to screen for prostate cancer in the U s. PSA testing measures for elevated levels of prostate specific-antigen antigen,
and engineered them to express a chimeric antigen receptor, or CAR, that would target cells expressing a protein called CD19.
which is something you usually only see with vaccines delivered by viruses. The albumin-targeted vaccines provoked immune responses five to 10 times stronger than those generated by the peptide antigens alone.
a recently discovered urinary antigen and a potential biomarker for bladder cancer. The new tool could be used as a high-throughput screening platform to identify patients at risk of developing the urologic condition.
The researchers first tested the immunoassay on a series of standard solutions containing A1at antigens at various concentrations in the range 10 to 1, 000 nanograms per milliliter.
They observed a'fingerprint'of A1at antigens spectral change in the 1, 850 to 2, 130 cm#1 region that increases with concentration.
or an antibody antigen reaction that only has expression for that specific cancer such as breast or prostate cancer.
We developed a nanoparticulate cancer vaccine by encapsulating a synthetic long peptide antigen within an immunologically inert nanoparticulate hydrogel (nanogel) of cholesteryl pullulan (CHP.
However, due to residual remnants of antigens such as sugar or other molecules, the human patients'immune cells are likely to attack the animal matrix.
The microfluidic device tests for the presence of the parasites'P23 antigen, a major molecular target of host antibody responses against the pathogen's infective stages.
which recognize and bind to antigens.""However, nanobodies are much smaller, more stable, easier to produce,
antigens and proteins naturally present on platelet membranes. This is unlike other efforts, which synthesize platelet mimics that replicate one or two surface proteins of the platelet membrane."
For example, chemotherapeutic agents used in the treatment of cancer are linked often chemically to antibodies that recognize antigens found only on the surface of the target tumor.
enolase, is a protective antigen and has several other functions that are essential for parasite growth and multiplication.
The international team found that the toxin split apart the red blood cells by attaching itself first to their so-called Duffy antigen protein receptor
Torres also has plans to study groups of Africans known to be genetically deficient in Duffy antigens and, hence, more resistant to malaria,
antigens and proteins naturally present on platelet membranes. This is unlike other efforts, which synthesize platelet mimics that replicate one or two surface proteins of the platelet membrane."
called an antigen. The result: The blood is more like type O, the universal donor. This isn the first time that researchers have produced blood with fewer antigens in the lab,
but this attempt has worked better than any other. The researchers used a technique called directed evolution;
Though this enzyme works pretty well to remove most antigens, it not perfect. That means that the treated blood isn a perfect type O,
and up to 12 hours from testing to confirmed diagnosis The test provides rapid, inexpensive, accurate detection of Ebola viral antigens based on colour change within 30 minutes in individuals
#Breast cancer vaccines may work better with silicon microparticles Model studies showed that microparticles loaded with an antigen, HER2,
not only protected the antigen from premature destruction, but also stimulated the immune system to recognize and relentlessly attack cancer cells overexpressing the HER2 antigen."
"We could completely inhibit tumor growth after just one dose of the cancer vaccine in the animal model,
In vivo and in vitro studies confirmed the microparticles stimulated a strong, sustained innate immune response at local sites of tumor activity and growth--with or without any antigen loaded."
"We have shown for the first time that a microparticle can serve as a carrier for sustained release and processing of tumor antigens,
and were transferred even from one antigen-presenting cell to another to maintain a long-lasting antigen-releasing effect."
In this case, HER2 is both a naturally occurring hormone receptor and an antigen target for therapy.
"PSMS persistently challenge the antigen-presenting cells to activate the T cells, "he said.""And the PSMS modify the tumor microenvironment
"Shen said the use of PSMS could work for any variety of cancer antigens and cancers,
and that the PSMS could be loaded with multiple antigens for a single vaccine target, or multiple antigens for several targets, possibly enhancing the approach's effectiveness further."
"Besides developing a highly potent breast cancer vaccine, we have demonstrated also that PSMS are said versatile, "Shen."
Shen said the researchers must evaluate the toxicity of antigen-loaded PSMS s
#Enzyme responsible for obesity-related high blood pressure identified"Hypertension is a condition in which arterial blood vessels are exposed to persistently elevated blood pressure,
"To be activated, T cells must first recognize an antigen, receive appropriate costimulatory signals, and then encounter inflammatory cytokines to expand the immune response.
enolase, is a protective antigen and has several other functions that are essential for parasite growth and multiplication.
but potentially to use the data for prevention. here are antigen-reactive T cells that are found in individuals at risk for type 1 diabetes,
have been refining cell-surface sensors known as chimeric antigen receptors, or CARS. Once inserted into T cells,
The engineered cells contain an antibody-like protein known as a chimeric antigen receptor (CAR) which is designed to bind to a protein called CD19 found on the surface of B cells including the cancerous B cells that characterize several types of leukemia.
and monitored by testing for high concentrations of prostate specific-antigen antigen (PSA) in blood samples. High PSA levels are followed often by a biopsy to confirm the presence of cancer,
which means the skin is reactive to an antigen such as peanuts especially by repeated exposure.
MIT researchers have shown that they can use a microfluidic cell-squeezing device to introduce specific antigens inside the immune system B cells,
and implementing antigen-presenting cell vaccines. Such vaccines, created by reprogramming a patient own immune cells to fight invaders,
a class of antigen-presenting cells with broad functionality in the immune system, the researchers demonstrate in a study published in Scientific Reports that B cells can be engineered to serve as an alternative. e wanted to remove an important barrier in using B cells as an antigen-presenting cell population,
helping them complement or replace dendritic cells, says Gregory Szeto, a postdoc at MIT Koch Institute for Integrative Cancer Research and the paper lead author.
A new vaccine-preparation approachdendritic cells are the most naturally versatile antigen-presenting cells. In the body, they continuously sample antigens from potential invaders,
which they process and present on their cell surface. The cells then migrate to the spleen or the lymph nodes,
or, targeting the specific antigens that are ingested and presented. Despite their critical role in the immune system
B cells are also antigen-presenting cells, but in contrast to dendritic cells, they can proliferate
Whereas dendritic cells constantly sample antigens they encounter, A b cell is programmed genetically only to bind to a specific antigen that matches the receptor on its surface.
As such, A b cell generally will not ingest and display an antigen if it does not match its receptor.
Using a microfluidic device, MIT researchers were able to overcome this genetically programmed barrier to antigen uptake by squeezing the B cells.
Through ellsqueeze, the device platform originally developed at MIT, the researchers pass a suspension of B cells and target antigen through tiny, parallel channels etched on a chip.
A positive-pressure system moves the suspension through these channels which gradually narrow, applying a gentle pressure to the B cells.
This queezeopens small, temporary holes in their membranes, allowing the target antigen to enter by diffusion.
This process effectively loads the cells with antigens to prime a response of CD8 or illert cells,
and found that they could expand antigen-specific T cells at least as well as existing methods using antibody-coated beads.
As proof of concept, the researchers then transferred squeezed B cells and antigen-specific T cells into mice
The researchers also say that this is the first method that decouples antigen delivery from B-cell activation.
when ingesting its antigen or when encountering a foreign stimulus that forces it to ingest nearby antigen.
This activation causes B cells to carry out very specific functions, which has limited options for B-cell-based vaccine programming.
of antigen-presenting cell vaccines.?The antigen-presenting capabilities of B cells have often been underestimated, but they are being appreciated increasingly for their practical advantages in therapies,
says Bishop, who was involved not in this research. his new technical approach permits loading B cells effectively with virtually any antigen
and has the additional benefit of targeting the antigens to the CD8 T-cell presentation pathway, thus facilitating the activation of the killer T cells desired in many clinical applications. ain squeezearmon Sharei, now a visiting scientist at the Koch Institute,
developed Cellsqueeze while he was a graduate student in the laboratories of Klavs Jensen, the Warren K. Lewis Professor of Chemical engineering and a professor of materials science and engineering,
While nucleic acids can code a cell for a target antigen these indirect methods have drawbacks:
They have limited ability in coding for difficult-to-identify antigens, and using nucleic acids bears a risk for accidental genome editing.
run it through a bedside device that has the antigen you want to vaccinate against, and then you have the vaccine,
and an associate professor of medicine in the division of hematology and oncology at the David Geffen School of medicine at UCLA. Kitchen and his colleagues were the first to report the use of an engineered molecule called a chimeric antigen receptor,
which is a two-part receptor that recognizes an antigen, was engineered to be carried by T cells
IV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells, Molecular Therapy,(8 june 2015;
Image via UCLATO conduct a traditional ELISA test, doctors place antigen samples from the patient onto a surface,
It is designed to detect antigens in samples of blood with an ELISA test used to detect a number of bacteria,
Blood samples are tested after specific antibodies that bind to antigens meet the blood in the embedded well portion of the plate.
Any antigens that may be present can be detected from analyzing the color changes. So how does the handheld ELISA diagnostic tool work?
In the clinical study, patientst-cells were engineered to express an affinity-enhanced T-cell receptor (TCR) specific for a type of tumor antigen,
or protein, known as a cancer-testis antigen (CT antigen). The target CT antigens were NY-ESO-1
and LAGE-1. Up to 60 percent of advanced myelomas have been reported to express NY-ESO-1 and/or LAGE-1,
which have been associated with another type of genetically engineered T-cells (chimeric antigen receptors, or CARS) used to treat other cancers.
or ELISA, is a diagnostic tool that identifies antigens such as viruses and bacteria in blood samples.
followed by small amounts of fluid containing specific antibodies that bind to antigens in the samples.
and quantify any antigens that may be present. The new device which is created with a 3d printer
Basically, you don have antibodies that recognize the new patterns on the virus (known as antigens) until youe encountered the new strain.
Each antibody can only detect a single antigen. But when it does find its match
A vaccine provides a template of antigens to train the immune response to recognize the new strains of influenza each year.
The prostate specific-antigen antigen (PSA) test was recommended once the screening tool for detecting prostate cancer, but there is now disagreement over the use of this test
which recognize and bind to antigens.""However, nanobodies are much smaller, more stable, easier to produce,
These so-called artificial antigen-presenting cells (aapcs) were pioneered by Schneck's lab and have shown promise in activating laboratory animals'immune systems to attack cancer cells.
and"present"them with distinctive proteins called antigens. This process activates the T cells to ward off a virus, bacteria or tumor,
humans with magnetic aapcs bearing antigens from tumors. They then ran the plasma through a magnetic column.
The researchers found that the technique also worked with a mixture of aapcs bearing multiple antigens,
While the team initially tested the new method only on cancer antigens, Schneck says it could also potentially work for therapies against chronic infectious diseases, such as HIV.
#Freshly squeezed vaccines (Nanowerk News) MIT researchers have shown that they can use a microfluidic cell-squeezing device to introduce specific antigens inside the immune systems B cells,
and implementing antigen-presenting cell vaccines. Such vaccines, created by reprogramming a patients own immune cells to fight invaders,
a class of antigen-presenting cells with broad functionality in the immune system, the researchers demonstrate in a study published in Scientific Reports("Ex Vivo Cytosolic Delivery of Functional Macromolecules to Immune Cells")that B cells can be engineered to serve as an alternative.
As a result, large molecules antigens, in the case of this study can enter before the membrane reseals.
Courtesy of SQZ Biotech) We wanted to remove an important barrier in using B cells as an antigen-presenting cell population,
A new vaccine-preparation approach Dendritic cells are the most naturally versatile antigen-presenting cells.
In the body, they continuously sample antigens from potential invaders which they process and present on their cell surface.
or, targeting the specific antigens that are ingested and presented. Despite their critical role in the immune system, dendritic cells have used drawbacks
B cells are also antigen-presenting cells, but in contrast to dendritic cells, they can proliferate
Whereas dendritic cells constantly sample antigens they encounter, A b cell is programmed genetically only to bind to a specific antigen that matches the receptor on its surface.
As such, A b cell generally will not ingest and display an antigen if it does not match its receptor.
Using a microfluidic device, MIT researchers were able to overcome this genetically programmed barrier to antigen uptake by squeezing the B cells.
Cellsqueezes microfluidic channels are etched on silicon chips and sealed with a glass layer. The channels temporarily deform cells
the researchers pass a suspension of B cells and target antigen through tiny, parallel channels etched on a chip.
temporary holes in their membranes, allowing the target antigen to enter by diffusion. This process effectively loads the cells with antigens to prime a response of CD8 or killer T cells,
which can then kill cancer cells or other target cells. The researchers studied the squeezed B cells in culture
and found that they could expand antigen-specific T cells at least as well as existing methods using antibody-coated beads.
and antigen-specific T cells into mice, observing that the squeezed B cells could expand T cells in the spleen and in lymph nodes.
The researchers also say that this is the first method that decouples antigen delivery from B-cell activation.
when ingesting its antigen or when encountering a foreign stimulus that forces it to ingest nearby antigen.
This activation causes B cells to carry out very specific functions, which has limited options for B-cell-based vaccine programming.
potential in the development of antigen-presenting cell vaccines. The antigen-presenting capabilities of B cells have often been underestimated,
but they are being appreciated increasingly for their practical advantages in therapies, says Bishop, who was involved not in this research.
This new technical approach permits loading B cells effectively with virtually any antigen and has the additional benefit of targeting the antigens to the CD8 T-cell presentation pathway
thus facilitating the activation of the killer T cells desired in many clinical applications. Main squeeze Armon Sharei, now a visiting scientist at the Koch Institute, developed Cellsqueeze while he was a graduate student in the laboratories of Klavs Jensen, the Warren K. Lewis Professor of Chemical engineering and a professor of materials science and engineering,
While nucleic acids can code a cell for a target antigen, these indirect methods have drawbacks:
They have limited ability in coding for difficult-to-identify antigens, and using nucleic acids bears a risk for accidental genome editing.
run it through a bedside device that has the antigen you want to vaccinate against, and then youd have the vaccine,
Corgenix provided the Reebov Antigen Rapid Test kits O
#Lexus Hoverboard Gets Off The Ground By Michael Greshko, Inside Science-In the classic 1989 film Back to the Future 2,
a team describes a new strategy that revolves around antibodies, immune proteins that target specific foreign proteins, called antigens.
One end of the antibody latches on to an antigen the other end, called the Fc region,
These regions go on form complexes with vaccine antigens, which then modulate the evolving vaccine response.
Their experiments revealed a complex interaction that ultimately pushes the B cells to produce antibodies with a higher affinity to their antigens.
antigen (PSA) screening. The study appears in the January issue of Clinical Chemistry (volume 61 page 239) which is dedicated to Molecular Diagnostics:
It belongs to a group of proteins known as"cancer/testis antigens, "which are expressed normally in the germ line cells that give rise to sperm and eggs,
"In this study, Huang and his colleagues focused on cancer testis antigens (CTAS), since they are often found in tumor cells that circulate in the blood.
Dr Dinglasan said as a vaccine antigen, Anapn1 prompts people to make antibodies; however only some of these antibodies block parasite transmission,
It will also prompt the redesign of the Anapn1 antigen to make it more effective e
A huge number of immature T cells, each of which can recognize a single antigen, are generated first,
In most parts of the body, antigens molecules on pathogens or foreign tissue that alert our immune system to potential threats are presented to white blood cells in our the lymph nodes causing an immune response.
Perhaps antigens from the infectious culprit find their way to the cervical lymph nodes via the meningeal lymphatic vessels,
and display pieces of viral or bacterial proteins (known as antigens) on their cell surfaces. When these B cells encounter T cells with receptors that recognize the antigen the T cells become activated provoking them to release cytokines inflammatory chemicals that control the immune response
or to seek out and destroy infected cells. Although all of the T cells in this study had identical T cell receptors the MIT team found that they did not all respond the same way after encountering B cells carrying identical antigens on their surfaces.
Using calcium imaging to measure T cell activation the researchers found that the initial activation level depends on how much of the antigen is presented.
At high levels most of the cells respond the same way. However at lower antigen levels the T cell responses vary greatly.
These differences also correlated to differences in T cell cytokine production. In future studies the researchers hope to further trace how T cells go through the decision-making process that determines their eventual fates.
Reebov is based a paper test that detects Ebola antigens. In addition to being easy to use in field or clinical settings,
I expected for a rapid antigen diagnostic test. his test can be done in very austere environments,
CAR stands for chimeric antigen receptor, which is the piece of the T cell modified to zero in on proteins on the surface of cancer cells.
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011